DREAMM9

A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma

What's the purpose of the trial?

This goal of this Phase 1 clinical trial is to test how safe and effective belantamab mafodotin is when combined with bortezomib, lenalidomide, and dexamethasone. Researchers want to determine the safest and most effective dose of belantamab mafodotin, and study whether it can improve your myeloma when combined with the other study drugs.

Trial status

Accepting patients

Phase
Phase 1
Enrollment
144
Last Updated
3 months ago
Patient Screener

Participating Centers

There are 6 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Belantamab Mafodotin is an antibody-drug conjugate (ADC) that binds to BCMA on tumor cell surfaces. Belantamab Mafodotin is used in the treatment of multiple myeloma.  
  • Bortezomib Bortezomib is a kind of medication called a proteasome inhibitor that interferes with the growth and spread of cancer cells in the body. Bortezomib is used to treat multiple myeloma and mantle cell lymphoma.
  • Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.